NeuroThera Labs Inc., a clinical-stage biotech company, announced that its collaboration with Clearmind Medicine Inc. has led to a patent application filed with the Intellectual Property Department in Hong Kong, China. The application covers an innovative combination therapy designed to treat major depressive disorder (MDD).
The therapy combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera. This MEAI-PEA synergy is positioned as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally according to a World Health Organization article titled "Depressive Disorder (Depression)" published in August 2025.
Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs) and other conventional options. The patent filing underscores the promise of this approach at a time when demand for novel treatments for major depressive disorder remains high.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics. The company's intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. For further information about Clearmind, visit https://www.clearmindmedicine.com.
Forward-looking information in the announcement includes statements regarding the potential therapeutic benefits of the MEAI-PEA combination therapy, its potential as a safer and more affordable alternative to existing antidepressants, and the presumed mechanism of action as a non-hallucinogenic neuroplastogen. These statements are not guarantees of future performance and involve known and unknown risks and uncertainties.
These risks include the early stage of development of the MEAI-PEA combination and the inherent uncertainty of preclinical and clinical outcomes. There is risk that the combination therapy may not demonstrate the anticipated safety, efficacy, or cost-effectiveness advantages over existing treatments for major depressive disorder. Additionally, the patent application filed in Hong Kong may not result in a granted patent, or any patent granted may not provide adequate protection for the combination therapy.
Other risks include the ability of the companies to advance the collaboration on acceptable terms, obtain required regulatory approvals, and maintain adequate intellectual property protection. General business, financial market, economic, competitive, political and social uncertainties also present challenges. More information about these risks is available in the Company's public filings on https://www.sedarplus.ca.
The importance of this development lies in addressing a global health crisis affecting hundreds of millions of people. Depression represents one of the leading causes of disability worldwide, and current treatments often come with significant side effects, limited efficacy for some patients, and accessibility challenges. If successful, this non-hallucinogenic neuroplastogen approach could expand treatment options for patients who don't respond to conventional antidepressants or who seek alternatives with different safety profiles.
For the pharmaceutical industry, this collaboration represents continued innovation in mental health therapeutics, particularly in the growing field of neuroplastogens that aim to promote neural plasticity without the hallucinogenic effects associated with some psychedelic compounds. The patent application in Hong Kong also reflects strategic intellectual property planning in key global markets.
